MAPKBP-1 Antibody (B-4): sc-514754

MAPKBP-1 Antibody (B-4) is a mouse monoclonal IgM kappa light chain antibody that detects MAPKBP-1 of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-MAPKBP-1 antibody (B-4) is available as a non-conjugated format. MAPKBP-1, also known as mitogen-activated protein kinase binding protein 1 or JNKBP-1, is a crucial 1,514 amino acid protein characterized by twelve WD repeats, which are important for protein-protein interactions. MAPKBP-1 plays a significant role in various cellular processes, including the activation of nuclear factor kappa-B (NFκB), a key regulator of immune response and inflammation. MAPKBP-1 is induced by TRAF2 (TNF receptor-associated factor 2) and Tak1 (TGF-beta-activated kinase 1), functioning as an adaptor protein that facilitates signaling pathways leading to NFκB activation. MAPKBP-1 interacts with JNK3 and may enhance TRAF2 polyubiquitination, thereby influencing cellular responses to stress and apoptosis. MAPKBP-1 is encoded on human chromosome 15, which is associated with several genetic disorders, highlighting MAPKBP-1′s importance in maintaining cellular homeostasis and potential implications in disease mechanisms.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MAPKBP-1 Antibody (B-4) References:

1. A novel Jun N-terminal kinase (JNK)-binding protein that enhances the activation of JNK by MEK kinase 1 and TGF-beta-activated kinase 1.  |  Koyano, S., et al. 1999. FEBS Lett. 457: 385-8. PMID: 10471813
2. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.  |  Khandoudi, N., et al. 2002. Diabetes. 51: 1507-14. PMID: 11978649
3. Structure of mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activation with nuclear export.  |  Meng, W., et al. 2002. J Biol Chem. 277: 37401-5. PMID: 12171911
4. Both binding and activation of p38 mitogen-activated protein kinase (MAPK) play essential roles in regulation of the nucleocytoplasmic distribution of MAPK-activated protein kinase 5 by cellular stress.  |  Seternes, OM., et al. 2002. Mol Cell Biol. 22: 6931-45. PMID: 12242275
5. Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells.  |  Falluel-Morel, A., et al. 2004. J Neurochem. 91: 1231-43. PMID: 15569266
6. JNK-binding protein 1 regulates NF-kappaB activation through TRAF2 and TAK1.  |  Yamaguchi, T., et al. 2009. Cell Biol Int. 33: 364-8. PMID: 19385034
7. Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.  |  Fu, L., et al. 2015. Oncotarget. 6: 8144-54. PMID: 25924238
8. Mutations in MAPKBP1 Cause Juvenile or Late-Onset Cilia-Independent Nephronophthisis.  |  Macia, MS., et al. 2017. Am J Hum Genet. 100: 323-333. PMID: 28089251
9. Mutations in MAPKBP1 Cause Juvenile or Late-Onset Cilia-Independent Nephronophthisis.  |  Macia, MS., et al. 2017. Am J Hum Genet. 100: 372. PMID: 28157543
10. Novel nephronophthisis-associated variants reveal functional importance of MAPKBP1 dimerization for centriolar recruitment.  |  Schönauer, R., et al. 2020. Kidney Int. 98: 958-969. PMID: 32505465
11. Novel pathogenic MAPKBP1 variant in a family with nephronophthisis.  |  Al-Hamed, MH., et al. 2021. Clin Kidney J. 14: 728-730. PMID: 33623699
12. Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans.  |  Cox, NJ., et al. 1999. Nat Genet. 21: 213-5. PMID: 9988276

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-MAPKBP-1 Antibody (B-4) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-MAPKBP-1 Antibody (B-4) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

MAPKBP-1 Antibody (B-4) Specifications

Alternate Product Name: MAPKBP-1

Product Clone Name: B-4

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM kappa light chain

Amino Acids: 48-61

Epitope Target: MAPKBP-1

Epitope Species: human

Product Reactivity/Detection: MAPKBP-1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for MAPKBP-1 Antibody (B-4): P: Blocking Peptide